BioLine RX BLRX 深 滬
已收盤 05-08 16:00:00 美东时间
3.07
-0.030
-0.97%
華盛通- 最 高3.1772
- 今 開3.14
- 成交量 1.28万股
- 最 低 3.00
- 昨 收 3.10
- 總市值 1335.87万
- 52周最高 7.7699
- 市盈率 靜 --
- 換手率 0.29%
- 52周最低 2.15
- 委 比 90.93%
- 總股本 435.14万
- 歷史最高 4122.00
- 量 比 0.46
- 振 幅 5.72%
- 歷史最低 2.15
- 每 手 1
- 風險率 0.74%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BioLineRx Announces That The First Patient Has Been Dosed In Its Phase 1/2A Study Of GLIX-1 For The Treatment Of Recurrent And Progressive Glioblastoma And Other High-Grade Gliomas
The GLIX1 program is being conducted under a collaboration between BioLineRx and Hemispherian announced in September 2025. The patient was dosed at NYU Langone Health under the supervision of Dr. Alexandra Miller, Chief
04-28 19:13
BioLineRx Launches First Human Trial For Brain Cancer Drug
BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced the initiation of a first-in-human, Phase
03-26 19:17
BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
GLIX1, a TET2 activator, is a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other cancers GLIX1 has demonstrated potent anti-tumor activity in multi...
03-26 19:00
BioLine Rx Q4 Sales $194.000K Miss $651.598K Estimate
BioLine Rx (NASDAQ:BLRX) reported quarterly sales of $194.000 thousand which missed the analyst consensus estimate of $651.598 thousand by 70.23 percent. This is a 98.35 percent decrease over sales of $11.749 million
03-23 19:16
Earnings Scheduled For March 23, 2026
Companies Reporting Before The Bell • Avalo Therapeutics (NASDAQ:AVTX) is likel...
03-23 19:11
BioLineRx Reports 2025 Financial Results and Provides Corporate Update
- On track to initiate Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) by end of this month - - GLIX1 is positioned to potentially address unmet needs for novel and mo...
03-23 19:00
Top Wall Street Forecasters Revamp BioLineRx Expectations Ahead Of Q4 Earnings
BioLineRx Ltd. (NASDAQ: BLRX) to release Q4 earnings on March 23. Previous Q3 losses were 22 cents per share, with sales of $427,000. Analysts rate the stock favorably.
03-20 14:45
Arbitrator Issues Final Award To BioLineRx, Denies All Claims By Biokine Therapeutics; Biokine To Pay Expenses And Legal Fees
https://ir.biolinerx.com/static-files/e6f7cf56-4605-44e6-8ed9-f0738b67b983
02-23 22:36
BioLine Rx Q3 EPADS $(0.22) Beats $(1.20) Estimate, Sales $427.000K Miss $990.000K Estimate
BioLine Rx (NASDAQ:BLRX) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(1.20) by 81.67 percent. This is a 214.29 percent decrease over losses of $(0.07) per share from the
2025-11-25 06:36
Earnings Scheduled For November 24, 2025
Companies Reporting Before The Bell • Lotus Technology (NASDAQ:LOT) is likely t...
2025-11-24 19:11
